#### INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

### **MEETING MINUTES**

Meeting Date:Friday, November 7, 2025Time:1:00 pm Eastern TimeLocation:Zoom Teleconference

Institution: Children's Healthcare of Atlanta, Inc., Altanta, GA

Principal Investigator: Hong Li, MD, PhD

Protocol: ModernaTX, Inc., mRNA-3705-P101

NCT Number: NCT04899310

Meeting Type: Initial Review of Protocol and Site

Title: A Global Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacodynamics,

and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic

Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

#### 1. Call to order:

The Meeting was called to order at 1:00 pm Eastern Time.

## 2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

### 3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

#### 4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

### 5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

### 6. Review of proposed research:

The Chair provided an overview of the protocol.

The Chair provided an overview of the biosafety risk assessment for the protocol.

# 7. Determination for biosafety level and period of IBC oversight:

The Committee determined that **BSL-1 containment facilities and practices plus Standard Precautions** are required for mRNA-3705 since it consists of lipid nanoparticle (LNP)-encapsulated mRNA administered in a clinical setting.

The Committee determined that IBC oversight will continue for **3 months after the last subject's last dose of mRNA-3705 locally** provided that all biosafety criteria for study closure are also met.

## 8. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

Χ	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5

NO: 0

ABSTAIN: 0

# 9. Review of Principal Investigator qualifications:

The Committee reviewed and accepted the qualifications of the Principal Investigator.

#### INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

# 10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

#### Points of Discussion:

- An Institutional Representative stated that the Biological Safety Cabinet (BSC) used for study agent preparation
  was recently re-certified. The Committee recommended that the institution submit the latest BSC Certification to
  IBC Services.
- 2. The Committee recommended that a small sharps container be placed inside the BSC and that site documents be revised to reflect this.
- 3. An Institutional Representative stated that a -80°C freezer will be available for study agent storage for this protocol. The Committee recommended that the freezer be labelled with a biohazard symbol and that a photo be submitted to IBC Services.
- 4. An Institutional Representative stated that pre-filled disposable eyewash bottles are available in all dosing rooms and there is a large supply onsite. The Committee recommended that site documents be revised to reflect this.
- 5. An Institutional Representative stated that dosing rooms will be used per their availability.

6.	An Institutional Representative stated that the	and the	
	are two different buildings.		

- The Committee recommended that the biohazard sign be posted at the entrance to the areas where the study agent is handled.
- 8. An Institutional Representative stated that PDI Super Sani-Cloth wipes are used to decontaminate work surfaces in the dosing rooms. The Committee recommended that site documents be revised to reflect this.
- An Institutional Representative confirmed that the study agent transport container is hard-sided. The Committee recommended that a biohazard symbol be placed on the transport container and that a new photo be submitted to IBC Services.

10. An Institution	Representative confirmed that a biohazardous waste container for disposal of PPE is available
in the	and will follow up with IBC Services on whether these are available in the dosing
rooms on the	

# 11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

11. An Institutional Representative stated that there are handwashing sinks in the

# 12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

### 13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 1:23 pm Eastern Time.

and